CKD-828 (40/5mg) Pharmacokinetic Study

Inclusion Criteria: * A healthy volunteer between 20 and 55 years old with body weight within 20% of ideal body weight. * Have not any congenital or chronic diseases and medical symptom. * Appropriate for the study judging from examinations(interview, vital signs, 12-lead ECG, physical examination, blood, urinalysis result on screening). * Able to participate in the entire trial. * Signed the informed consent form prior to the study participation. Exclusion Criteria: * Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days prior to the first IP administraion. * The evidence of acute disease within 28 days prior to the first IP administraion. * Disease(ex: imflammatory intestinal disease, gastric or duodenal ulcer ,hepatic diseasehistory , gastro intestinal surgery exept for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug(s). * Relevant hypersensitivity against drug or clinically significant allergic diseases except mild rhinitis that doesn't need medication. * Hypersensitivity Telmisartan or Amlodipine. * SBP\<90mmHg or DBP\<50mmHg. * Abnormal laboratory result(s): AST or ALT \> 1.25 times of upper limit / Total bilirubin \> 1.5 times of upper limit. * A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or a heavy smoker(more than 10 cigarettes per a day) or a regular alcohol consumer(more than 30g/day) or drinking within 7days prior to the first IP administration. * Diet(Especially, grapefruit juice-within 7 days prior to the first IP administraion) that may influence on the absorption, distribution, metabolism and excretion of the drug(s). * Donated whole blood within 60 days prior to the first IP administraion. * Participated in the other clinical trials within 90days prior to the first IP administraion. * Medicine within 10 days prior to the first IP administraion? Does the medication affect this trial. * Appropriate for the trial judging from principal investigator.